Fluticasone Nasal

Introduction Overview

Generic Name

fluticasone nasal

Brand Name

Children's Flonase, Flonase Allergy Relief, Flonase Sensimist, Good Sense Allergy Relief (Fluticasone), Good Sense Children's Allergy Relief, Xhance, Flonase, Veramyst, Good Sense Nasoflow

Dosage Form

nasal spray (27.5 mcg/inh; 50 mcg/inh; 93 mcg/inh)

Drug Class

Nasal steroids

Pharmacokinetics

Fluticasone nasal exhibits complex pharmacokinetic properties tailored to intranasal delivery.

Absorption:
Fluticasone nasal sprays are designed to deliver drug locally to the nasal mucosa, minimizing systemic absorption. The drug exhibits low oral bioavailability (<1%) due to extensive first-pass metabolism, which limits systemic exposure when swallowed. Absorption through the nasal mucosa occurs slowly with a small fraction entering systemic circulation. Intranasal administration achieves rapid onset of action at the mucosal surface. Clinical studies note that peak plasma concentrations after nasal administration are low and occur approximately 1 to 2 hours post-dose. Factors such as nasal mucosal health and coexisting nasal pathology can impact absorption.

Distribution:
Once absorbed systemically, fluticasone exhibits a high volume of distribution (approximately 4 L/kg), indicating extensive distribution to peripheral tissues. It is extensively bound (>90%) to plasma proteins, primarily albumin, reducing free circulating drug levels. The drug’s lipophilic nature facilitates penetration into nasal tissues, ensuring sustained local anti-inflammatory effects. Fluticasone distributes poorly into the central nervous system due to active efflux transporters. Tissue selectivity to nasal mucosa enables targeted efficacy with limited systemic side effects.

Metabolism:
Fluticasone nasal is extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) enzymes in the liver. The parent compound undergoes oxidative metabolism to inactive metabolites. This metabolism accounts for the drug’s low systemic bioavailability and short systemic half-life. Enzyme induction or inhibition, such as with strong CYP3A4 inhibitors or inducers, can significantly alter plasma levels and increase systemic exposure, raising risk for adverse effects. Non-hepatic metabolism and local nasal enzymatic activity also contribute to clearance.

Elimination:
The inactive metabolites of fluticasone are predominantly eliminated via feces (>80%) through biliary excretion, with minimal renal clearance of unchanged drug (<1%). The systemic elimination half-life is approximately 7-8 hours. Intranasal delivery reduces systemic exposure, and the majority of the dose is cleared nasally or swallowed and inactivated via gut metabolism. Accumulation with repeated dosing is minimal. Clinical implications of elimination include the necessity for once or twice daily dosing to maintain therapeutic concentrations and minimize systemic steroid-related adverse effects.

Dosage Forms

Available Dosage Forms:
Fluticasone nasal is available as a nasal spray delivered through metered-dose inhalers with varying strengths:
- Nasal spray with 27.5 mcg per inhalation (fluticasone furoate)
- Nasal spray with 50 mcg per inhalation (fluticasone propionate)
- Nasal spray with 93 mcg per inhalation (used in formulations such as Xhance)

Dosages for Adults and Adolescents:
- Fluticasone furoate: Typically dosed as 2 sprays (27.5 mcg/spray) in each nostril once daily for adults; once maximum benefit is achieved, dose reduction to 1 spray (27.5 mcg) in each nostril once daily may be effective.
- Fluticasone propionate: Commonly dosed as 1 or 2 sprays (50 mcg/spray) in each nostril once daily as needed for adults and children 12 years or older.
- For pediatric population from 4 years, fluticasone propionate is usually dosed as 1 spray (50 mcg) per nostril once daily.

Specific Patient Populations:
- Children aged 2 to 11 years may use fluticasone furoate 1 spray in each nostril once daily; dose escalation to 2 sprays per nostril daily may be considered if symptom control is inadequate.
- Xhance nasal spray, with higher dose (93 mcg/spray), is indicated for adults for chronic rhinosinusitis with nasal polyps; use in children is not established.
- Dosing adjustments should consider patients’ age, symptom severity, and response to therapy.
- Patients with hepatic impairment may require monitoring due to metabolism via CYP3A4.

Clinical guidelines emphasize adherence to specific dosing instructions and supervision in pediatric use to optimize efficacy and safety.

Mechanism Of Action

Fluticasone nasal acts as a potent synthetic corticosteroid with anti-inflammatory properties localized to the nasal mucosa. Upon administration, it exerts its primary effect by binding to glucocorticoid receptors (GR) in target cells, leading to modulation of gene expression that suppresses inflammatory processes.

At the molecular level, fluticasone binds intracellular GRs, causing receptor activation and translocation into the nucleus where it interacts with glucocorticoid response elements (GREs) in the DNA. This interaction results in upregulation of anti-inflammatory proteins such as lipocortin-1, which inhibits phospholipase A2, effectively reducing the synthesis of arachidonic acid-derived inflammatory mediators including prostaglandins and leukotrienes.

Concurrently, fluticasone inhibits the expression of pro-inflammatory genes encoding cytokines (e.g., IL-1, IL-6, TNF-alpha), chemokines, adhesion molecules, and enzymes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), thereby diminishing cellular infiltration and inflammatory responses in the nasal mucosa. This broad suppression leads to reduced nasal congestion, rhinorrhea, sneezing, and itching.

Clinically, this mechanism provides relief of symptoms in allergic rhinitis, chronic rhinosinusitis, and other upper airway inflammatory conditions. Compared to systemic corticosteroids, nasal administration of fluticasone achieves targeted delivery with minimal systemic absorption, reducing common steroid-associated adverse effects. Extensive clinical research supports its efficacy and superior safety profile in managing seasonal and perennial allergic rhinitis and nasal polyposis.

Pharmacological Actions

Potent anti-inflammatory effect through glucocorticoid receptor activation.
Suppression of cytokine and chemokine production reducing immune cell recruitment.
Inhibition of phospholipase A2 activity, decreasing leukotriene and prostaglandin synthesis.
Reduction of nasal mucosal edema and vascular permeability leading to decreased congestion.
Decreased mast cell activation and mediator release in allergic responses.
Local immunosuppressive effect minimizing hypersensitivity reactions in nasal tissues.
Improvement of nasal airway patency and reduction of nasal hyperreactivity.
Minimal systemic glucocorticoid effects due to low bioavailability and extensive first-pass metabolism.
Long duration of action allowing convenient once-daily dosing in certain formulations.
Symptom control in seasonal and perennial allergic rhinitis as well as chronic rhinosinusitis.
Reduction in sneezing, rhinorrhea, nasal pruritus and ocular symptoms associated with allergies.
Steroid action reduces inflammatory nasal polyps size and associated obstruction in chronic rhinosinusitis.
Has mild vasoconstrictive properties contributing to relief of nasal congestion.
Exerts effects on multiple inflammatory cell types including eosinophils, T-lymphocytes, and macrophages.
Demonstrates improvement in quality of life measures related to allergic nasal diseases.

Therapeutic Or Clinical Uses

Treatment of seasonal allergic rhinitis (hay fever) symptoms including sneezing, runny nose, and nasal congestion.
Management of perennial allergic rhinitis due to year-round allergens such as dust mites and pet dander.
Relief of nasal inflammation and symptoms associated with chronic rhinosinusitis.
Reduction of nasal polyps and improvement of nasal airway obstruction in chronic rhinosinusitis with nasal polyps (Xhance formulation).
Control of nasal symptoms in adults and children with allergic rhinitis.
Adjunct therapy in allergic conjunctivitis by reducing ocular itching and watering.
Treatment of nonallergic rhinitis with nasal mucosal inflammation.
Symptomatic relief for patients with nasal congestion due to environmental irritants.
Prophylactic use in patients with predictable seasonal allergy exacerbations.
Maintenance therapy to reduce frequency and severity of nasal allergy attacks.
Alternative to systemic corticosteroids to avoid systemic side effects in allergic airway diseases.
Use in patients with asthma or atopic conditions to control nasal inflammation and reduce lower airway symptoms.
Treatment of nasal symptoms in pediatric populations with age-appropriate dosing.
Off-label use in other inflammatory nasal conditions as judged by clinicians.
Part of combination therapy with antihistamines or decongestants when monotherapy is insufficient.

Side Or Adverse Effects

Nasal irritation including burning, dryness, or itching sensation in the nose.
Minor and occasional nosebleeds (epistaxis) due to mucosal dryness or fragility.
Sore throat or nasal mucosal ulcerations and white patches.
Nasal crusting and discomfort especially with prolonged use or improper technique.
Headache, which may be related to local irritation or systemic absorption.
Cough or throat irritation secondary to nasal drip of medication.
Potential blurred vision or eye pain, indicating possible corticosteroid-induced ocular effects.
Symptoms of local infection such as redness, sores, or white patches inside the nose or throat.
Rare systemic corticosteroid effects including hormonal imbalances with long-term overuse.
Possible slowed growth in children with extended use requiring monitoring.
Increased susceptibility to upper respiratory tract infections due to local immunosuppression.
Allergic reactions including rash, hives, facial swelling, or breathing difficulty (rare).
Worsening of pre-existing fungal or bacterial infections of the nasal mucosa.
Systemic side effects such as muscle weakness, fatigue, or hormonal disorders with improper use.
Gastrointestinal symptoms such as nausea or vomiting reported in some cases.

Precautions

Evaluate for allergy to fluticasone or any component prior to use to avoid hypersensitivity reactions.
Advise patients against abrupt cessation if switching from systemic steroids; taper dose appropriately.
Monitor pediatric patients for growth suppression during chronic use of nasal steroids.
Use cautiously in patients with active nasal infections, ulcers, or recent nasal surgery to prevent exacerbations.
Inform patients about proper inhaler technique to minimize nasal irritation and optimize drug delivery.
Avoid exposure to people with contagious infections such as measles or chickenpox during therapy.
Assess for glaucoma or cataracts history, as prolonged intranasal steroid use can increase risk.
Consider hepatic impairment and potential CYP3A4 interactions which may increase systemic exposure.
Advise patients to avoid spraying into the eyes or mouth to reduce local adverse effects and irritation.
Use the lowest effective dose for the shortest duration consistent with symptom control.
Educate patients on recognizing signs of adverse effects such as nasal bleeding or persistent soreness.
Monitor for signs of systemic corticosteroid effects particularly with high-dose or long-term use.
Pregnant or breastfeeding women should consult healthcare providers before use.
Patients with diabetes should monitor blood glucose as corticosteroids may affect glycemic control.
Ensure patients understand that symptomatic relief may take several days; adherence is important.

Warnings

Do not use if allergic to fluticasone or any ingredients in the nasal spray formulation.
Risk of immunosuppression leading to increased susceptibility to infections or worsening existing infections.
Severe or ongoing nosebleeds require immediate medical attention to rule out mucosal damage.
Potential for glaucoma or cataracts with prolonged or inappropriate use; regular ophthalmologic assessment recommended.
Avoid contact of spray with eyes or mouth to prevent irritation or adverse ocular effects.
Long-term use may result in systemic corticosteroid side effects including adrenal suppression.
Use cautiously in patients with recent nasal surgery or trauma to avoid delayed healing or complications.
Be alert for signs of hormonal disorders such as muscle weakness, fatigue, nausea, or vomiting during therapy.
Risk of slowed growth velocity in children; monitor growth during chronic use.
Avoid sudden discontinuation after long-term use to prevent adrenal insufficiency.
Exposure to varicella or measles during treatment may lead to severe or fatal infections.
Monitor for local nasal fungal infections or thrush with prolonged corticosteroid exposure.
Patients should inform healthcare providers about all medications to avoid interactions.
Do not share nasal spray devices to prevent cross contamination.
Store spray properly and discard after recommended number of sprays to ensure dosing accuracy and sterility.

Contraindication

Known hypersensitivity or allergy to fluticasone or any excipients in the nasal spray.
Active untreated nasal infections, including fungal, bacterial, or viral infections of the nasal mucosa.
Patients with recent nasal surgery or nose injury until healing is complete.
Use avoidance in patients with hypersensitivity reactions to corticosteroids.
Contraindicated in patients who have experienced severe adverse effects or allergic reactions to similar nasal corticosteroids.
Not recommended for use in children under 2 years of age for most fluticasone nasal formulations.
Contraindicated in uncontrolled glaucoma or untreated cataracts without precautionary measures.
Not to be used in patients with systemic fungal infections due to potential immunosuppression.
Should not be used as sole therapy for severe acute asthma or anaphylaxis.
Avoid use in patients receiving immunosuppressive doses of other systemic steroids unless under close supervision.
Patients with known hypersensitivity to the preservative agents used in certain formulations may be contraindicated.
Avoid use in patients with active tuberculosis involving nasal mucosa.
Not intended for treatment of nasal decongestion from acute infections such as the common cold without appropriate diagnosis.
Contraindicated if patient has demonstrated intolerance to fluticasone nasal spray components or delivery devices.
Should not be used as a substitute for systemic corticosteroids in patients requiring systemic steroid therapy.

Drug Interactions

Concomitant use with potent CYP3A4 inhibitors (such as ketoconazole, ritonavir) can increase systemic fluticasone levels leading to enhanced risk of systemic corticosteroid effects.
Antifungal medications may potentiate the effects of fluticasone by reducing its metabolism.
Antiviral drugs used for hepatitis C or HIV/AIDS may alter fluticasone metabolism, increasing systemic exposure.
Co-administration with other intranasal steroids or systemic corticosteroids may increase risk of cumulative steroid adverse effects.
Caution with immunosuppressive agents due to additive immunosuppression and infection risk.
Interactions with other nasal products such as decongestants require monitoring for nasal mucosal irritation.
Use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce fluticasone efficacy by increasing clearance.
Concurrent use with vaccines, especially live vaccines, may lead to altered immune responses.
Limited data on interactions with antihistamines; however, combined therapy is common and should be monitored.
Potential interaction with diabetes medications as corticosteroids can increase blood glucose levels.
Co-administration with warfarin and other anticoagulants requires monitoring for altered coagulation parameters.
Interaction potential with grapefruit juice is low but caution is advised given CYP3A4 metabolism.
Use caution when combined with cyclosporine due to immunosuppressive effects.
Concurrent use with diuretics might increase risk for hypokalemia.
Herbal supplements affecting CYP3A4 (e.g., St. John's Wort) may alter fluticasone metabolism and effectiveness.

Preparations Of The Drug

Fluticasone nasal spray 27.5 mcg per spray (fluticasone furoate) – commercial products such as Veramyst.
Fluticasone nasal spray 50 mcg per spray (fluticasone propionate) – products include Flonase and Flonase Allergy Relief.
Fluticasone nasal spray 93 mcg per spray (fluticasone propionate) – marketed as Xhance with unique exhalation delivery system.
Children-specific formulations with age-appropriate dosing, e.g., Good Sense Children’s Allergy Relief.
Preservative-containing and preservative-free formulations depending on brand and country availability.
Metered dose spray pump delivering precise microgram quantities per actuation.
Packaging with dosing counters to track number of sprays used.
Instruction leaflets provided for proper administration technique and dosing schedules.
Some products are available as over-the-counter (OTC) while others require prescription.
Sprays formulated to reduce drip and irritation with excipients optimizing mucosal adherence.
Product variants designed for sensitive mucosa, such as Flonase Sensimist.
Storage recommendations include room temperature, upright position, away from moisture and heat.
Disposable or non-refillable spray bottles typically containing 120 sprays per container.
Some formulations approved for use in children as young as 2 years (Veramyst).
Advanced formulations utilizing exhalation delivery technology to improve reaching posterior nasal passages (Xhance).